

Hematologic Malignancies

BloodCenter of Wisconsin: Focused on success with your patient

The Diagnostic Laboratories at BloodCenter of Wisconsin offer a wide variety of highly specialized diagnostic services to physicians and patients around the globe, with emphasis on the diagnosis of blood diseases. We partner with physicians to help them

make the best treatment decisions for their patients through timely, actionable consultation. We continually focus on developing new assays and technologies to advance patient care and improve patient outcomes.

NEXT GENERATION SEQUENCING HEMEONC PANEL FOR HEMATOLOGIC MALIGNANCIES

At BloodCenter's Diagnostic Laboratories, we never lose sight of why our work with you is important. Like you, our team is dedicated to delivering the very best care for your patient. That's why, from start to finish, we are your partner every step of the way.



BloodCenter's NGS HemeOnc Panel

NEXT GENERATION SEQUENCING (NGS) IS A TRANSFORMATIVE TECHNOLOGY FOR MOLECULAR DIAGNOSTICS

Comprehensive genetic profiling of hematologic malignancies through NGS is increasingly useful for patient care. The information we generate directly impacts diagnosis, prognosis, risk stratification and the selection of appropriate therapy.

Using this cutting-edge technology, BloodCenter of Wisconsin is able to sequence multiple gene targets simultaneously. With this technological capability it is possible to interrogate more regions in the genome, looking at more targets and regions that are relevant to a particular disease state. This is especially important for cancer patients because we can look at more genes that may be relevant to or impacting the patient's tumor.

The capability to interrogate multiple targets in the genome simultaneously in a single assay with NGS allows BloodCenter of Wisconsin to provide more information at a lower cost and a faster turnaround time. Our NGS HemeOnc panel looks at 30 different genes potentially involved in the pathogenesis of myeloid hematologic malignancies.

Dr. D.P. Dash, Director, Molecular Oncology Laboratory and Dr. Matt Anderson, Medical Director, Diagnostic Laboratories, BloodCenter of Wisconsin, review our unique comprehensive diagnostic report.

BLOODCENTER'S UNIQUE OFFERING – COMPREHENSIVE DIAGNOSTIC REPORT

The value that BloodCenter provides extends beyond the testing. Our comprehensive diagnostic report includes the latest information on clinical significance of sequence variants, potential therapeutic options and applicable clinical trials. This information empowers physicians to more readily determine the appropriate treatment for their patients, leading to exceptional value in improved patient care and outcomes.

BloodCenter's medical team is always available to consult on patient cases. In fact, we help physicians resolve some of the most difficult cases they encounter. Our laboratory directors, scientists and staff are dedicated to providing the best possible patient care.



*“The information we generate directly impacts diagnosis, prognosis, risk stratification and the appropriate therapy.”
– Dr. D.P. Dash*

“The expert consultation that accompanies the test differentiates BloodCenter of Wisconsin's NGS platform. The trustworthiness of their tests and the timeliness are critical, and are already part of our relationship with BloodCenter.”

– Dr. Parameswaran Hari, MCRP, Clinical Director, Adult Bone Marrow Transplant Program, Froedtert & The Medical College of Wisconsin Cancer Center



Disease State	Genes Tested						
	JAK2 V617F	ASXL1	MPL EXON10	IDH1/2	JAK2 EXON12	TET2	EZH2
Myeloproliferative Neoplasms (MPN)	JAK2 V617F	ASXL1	MPL EXON10	IDH1/2	JAK2 EXON12	TET2	EZH2
	LNK (SH2B3)	U2AF1	ETV6				
Juvenile Myelomonocytic Leukemia (JMML)	NRAS	KRAS	CBL	PTPN1	SETBP1	TET2	JAK3
Refractory Anemia w/Ringed Sideroblasts assoc. w/ marked Thrombocytosis (RARS-T)	JAK2 V617F	MPL	SF3B1	TET2	DNMT3A		
Chronic Myelomonocytic Leukemia (CMML)	NRAS	KRAS	CBL	TET2	EZH2	ASXL1	RUNX1
	JAK2 V617F	CSF3R	SETBP1	SRSF2			
Myelodysplastic Syndromes (MDS)	NRAS	KRAS	IDH1/2	TET2	EZH2	ASXL1	RUNX1
	TP53	DNMT3A	SF3B1	U2AF1	ETV6	GATA2	
Acute Myeloid Leukemia (AML)	FLT3	NPM1	CEBPA	TP53	IDH1/2	DNMT3A	TET2
	CSF3R	SRSF2	GATA2	KIT	NRAS	RUNX1	WT1
	ASXL1	SF3B1	PHF6	U2AF1	ETV6	JAK3 (AMKL)	
Chronic Neutrophilic Leukemia (CNL)	CSF3R	SETBP1					
Chronic Myelogenous Leukemia (CML)	ABL1	ETV6					
Atypical Chronic Myelogenous Leukemia (aCML)	SETBP1						
Severe Congenital Neutropenia (SCN)	CSF3R						